Form 4: Teladoc Health Executive Sells Shares After Stock Unit Vesting

Sentiment:

SEC Form 4 Filing


A Teladoc Health executive, Fernando M. Rodrigues, sold shares to cover tax obligations after restricted stock units vested.

Summary

  • Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, engaged in transactions involving the company's common stock.
  • On November 29, 2024, 21,964 restricted stock units vested and converted to common stock.
  • Following the vesting, Mr. Rodrigues sold 7,873 shares on December 2, 2024, at an average price of $11.927 per share.
  • He then sold an additional 14,091 shares on December 3, 2024, at a weighted average price of $11.071 per share.
  • These sales were primarily to cover tax withholding obligations related to the vesting of the restricted stock units.
  • After these transactions, Mr. Rodrigues directly owns 0 shares of common stock.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions related to compensation. It is neither particularly positive nor negative from an investment perspective.

Risks

  • Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a routine filing related to executive compensation and stock transactions, which is common in publicly traded companies. It does not indicate any specific trend in the telehealth industry.

Comparison to Industry Standards

  • Executive stock sales are a common occurrence in publicly traded companies, particularly after vesting periods for equity compensation.
  • The sale of shares to cover tax obligations is a standard practice and does not necessarily indicate a negative outlook on the company's future.
  • Similar transactions are regularly reported by executives at comparable companies in the healthcare and technology sectors.

Stakeholder Impact

  • The stock sales may have a minor impact on the stock price, but it is unlikely to be significant given the routine nature of the transactions.
  • The transactions do not directly impact employees, customers, or suppliers.

Key Dates

DateDescription
12/01/2023The reporting person was granted 65,894 restricted stock units.
11/29/202421,964 restricted stock units vested and converted to common stock.
12/02/20247,873 shares were sold at an average price of $11.927.
12/03/202414,091 shares were sold at a weighted average price of $11.071.

Keywords

Teladoc Health, TDOC, stock sale, restricted stock units, insider trading, executive compensation, Form 4, Fernando M. Rodrigues, BetterHelp

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.